Based on the paradigm of EGFR targeting by osimertinib, it is becoming clear that other genotype-matched therapeutics, currently approved for advanced-stage NSCLC, might provide clinical benefit in the adjuvant setting. Here, EGFR is linked to non-small cell lung carcinoma.